Artisan Partners Limited Partnership Has $104.89 Million Stake in Medtronic PLC $MDT

Artisan Partners Limited Partnership lowered its position in Medtronic PLC (NYSE:MDT) by 2.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,203,236 shares of the medical technology company’s stock after selling 24,514 shares during the period. Artisan Partners Limited Partnership owned 0.09% of Medtronic worth $104,886,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of MDT. Gilbert & Cook Inc. raised its position in Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after purchasing an additional 114 shares during the last quarter. Red Spruce Capital LLC grew its holdings in shares of Medtronic by 0.5% during the second quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after purchasing an additional 118 shares during the last quarter. Certior Financial Group LLC increased its stake in shares of Medtronic by 3.7% in the first quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after buying an additional 122 shares in the last quarter. PrairieView Partners LLC raised its holdings in shares of Medtronic by 3.6% in the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock valued at $324,000 after buying an additional 128 shares during the last quarter. Finally, Motco lifted its position in Medtronic by 27.0% during the 1st quarter. Motco now owns 635 shares of the medical technology company’s stock worth $57,000 after buying an additional 135 shares in the last quarter. 82.06% of the stock is currently owned by institutional investors.

Medtronic Price Performance

Shares of MDT stock opened at $100.12 on Thursday. The firm’s 50 day moving average price is $94.80 and its two-hundred day moving average price is $90.70. The stock has a market cap of $128.42 billion, a PE ratio of 27.58, a PEG ratio of 2.42 and a beta of 0.77. Medtronic PLC has a 52-week low of $79.29 and a 52-week high of $102.59. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the business posted $1.26 EPS. The firm’s quarterly revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on MDT shares. Leerink Partners set a $120.00 price objective on shares of Medtronic and gave the stock an “outperform” rating in a report on Wednesday. Royal Bank Of Canada increased their price target on shares of Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a research note on Wednesday. Wells Fargo & Company boosted their price objective on shares of Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research report on Wednesday. Wall Street Zen lowered Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday, November 2nd. Finally, Truist Financial lifted their target price on Medtronic from $96.00 to $103.00 and gave the company a “hold” rating in a research note on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $108.50.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction that occurred on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total transaction of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William R. Jellison acquired 2,500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were purchased at an average price of $92.37 per share, with a total value of $230,925.00. Following the acquisition, the director owned 5,000 shares of the company’s stock, valued at approximately $461,850. This trade represents a 100.00% increase in their position. The SEC filing for this purchase provides additional information. 0.26% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.